333 related articles for article (PubMed ID: 30323975)
1. Deglycosylation of PD-L1 by 2-deoxyglucose reverses PARP inhibitor-induced immunosuppression in triple-negative breast cancer.
Shao B; Li CW; Lim SO; Sun L; Lai YJ; Hou J; Liu C; Chang CW; Qiu Y; Hsu JM; Chan LC; Zha Z; Li H; Hung MC
Am J Cancer Res; 2018; 8(9):1837-1846. PubMed ID: 30323975
[TBL] [Abstract][Full Text] [Related]
2. Saccharide analog, 2-deoxy-d-glucose enhances 4-1BB-mediated antitumor immunity via PD-L1 deglycosylation.
Kim B; Sun R; Oh W; Kim AMJ; Schwarz JR; Lim SO
Mol Carcinog; 2020 Jul; 59(7):691-700. PubMed ID: 32115801
[TBL] [Abstract][Full Text] [Related]
3. Aptamer targeted therapy potentiates immune checkpoint blockade in triple-negative breast cancer.
Camorani S; Passariello M; Agnello L; Esposito S; Collina F; Cantile M; Di Bonito M; Ulasov IV; Fedele M; Zannetti A; De Lorenzo C; Cerchia L
J Exp Clin Cancer Res; 2020 Sep; 39(1):180. PubMed ID: 32892748
[TBL] [Abstract][Full Text] [Related]
4. Eradication of Triple-Negative Breast Cancer Cells by Targeting Glycosylated PD-L1.
Li CW; Lim SO; Chung EM; Kim YS; Park AH; Yao J; Cha JH; Xia W; Chan LC; Kim T; Chang SS; Lee HH; Chou CK; Liu YL; Yeh HC; Perillo EP; Dunn AK; Kuo CW; Khoo KH; Hsu JL; Wu Y; Hsu JM; Yamaguchi H; Huang TH; Sahin AA; Hortobagyi GN; Yoo SS; Hung MC
Cancer Cell; 2018 Feb; 33(2):187-201.e10. PubMed ID: 29438695
[TBL] [Abstract][Full Text] [Related]
5. The combined effect and mechanism of antiangiogenic drugs and PD-L1 inhibitor on cell apoptosis in triple negative breast cancer.
Li J; Zhang D; Liu Z; Wang Y; Li X; Wang Z; Liang G; Yuan X; Li Y; Komorowski AL; Rozen WM; Orlandi A; Takabe K; Franceschini G; Jerusalem G; Wang X
Ann Transl Med; 2023 Jan; 11(2):83. PubMed ID: 36819490
[TBL] [Abstract][Full Text] [Related]
6. Inhibition of MYC suppresses programmed cell death ligand-1 expression and enhances immunotherapy in triple-negative breast cancer.
Li X; Tang L; Chen Q; Cheng X; Liu Y; Wang C; Zhu C; Xu K; Gao F; Huang J; Wang R; Guan X
Chin Med J (Engl); 2022 Oct; 135(20):2436-2445. PubMed ID: 36583862
[TBL] [Abstract][Full Text] [Related]
7. Emerging strategies: PARP inhibitors in combination with immune checkpoint blockade in BRCA1 and BRCA2 mutation-associated and triple-negative breast cancer.
Gupta T; Vinayak S; Telli M
Breast Cancer Res Treat; 2023 Jan; 197(1):51-56. PubMed ID: 36318381
[TBL] [Abstract][Full Text] [Related]
8. Atezolizumab potentiates Tcell-mediated cytotoxicity and coordinates with FAK to suppress cell invasion and motility in PD-L1
Mohan N; Hosain S; Zhao J; Shen Y; Luo X; Jiang J; Endo Y; Wu WJ
Oncoimmunology; 2019; 8(9):e1624128. PubMed ID: 31428520
[TBL] [Abstract][Full Text] [Related]
9. A Systematic Review on the Therapeutic Potentiality of PD-L1-Inhibiting MicroRNAs for Triple-Negative Breast Cancer: Toward Single-Cell Sequencing-Guided Biomimetic Delivery.
Shadbad MA; Safaei S; Brunetti O; Derakhshani A; Lotfinejad P; Mokhtarzadeh A; Hemmat N; Racanelli V; Solimando AG; Argentiero A; Silvestris N; Baradaran B
Genes (Basel); 2021 Aug; 12(8):. PubMed ID: 34440380
[TBL] [Abstract][Full Text] [Related]
10. Current situation of programmed cell death protein 1/programmed cell death ligand 1 inhibitors in advanced triple-negative breast cancer.
Liang Y; Liu X; Li K; Li H
Chin J Cancer Res; 2022 Apr; 34(2):117-130. PubMed ID: 35685994
[TBL] [Abstract][Full Text] [Related]
11. STAT3 and PD-L1 are negatively correlated with ATM and have impact on the prognosis of triple-negative breast cancer patients with low ATM expression.
Song YM; Qian XL; Xia XQ; Li YQ; Sun YY; Jia YM; Wang J; Xue HQ; Gao GS; Wang XZ; Zhang XM; Guo XJ
Breast Cancer Res Treat; 2022 Nov; 196(1):45-56. PubMed ID: 36056297
[TBL] [Abstract][Full Text] [Related]
12. BRD4 inhibition suppresses PD-L1 expression in triple-negative breast cancer.
Jing X; Shao S; Zhang Y; Luo A; Zhao L; Zhang L; Gu S; Zhao X
Exp Cell Res; 2020 Jul; 392(2):112034. PubMed ID: 32339606
[TBL] [Abstract][Full Text] [Related]
13. Breast Cancer Cells and PD-1/PD-L1 Blockade Upregulate the Expression of PD-1, CTLA-4, TIM-3 and LAG-3 Immune Checkpoints in CD4
Saleh R; Toor SM; Khalaf S; Elkord E
Vaccines (Basel); 2019 Oct; 7(4):. PubMed ID: 31614877
[No Abstract] [Full Text] [Related]
14. Mechanisms and Strategies to Overcome PD-1/PD-L1 Blockade Resistance in Triple-Negative Breast Cancer.
Chen X; Feng L; Huang Y; Wu Y; Xie N
Cancers (Basel); 2022 Dec; 15(1):. PubMed ID: 36612100
[TBL] [Abstract][Full Text] [Related]
15. PD-L1 expression in tumor lesions and soluble PD-L1 serum levels in patients with breast cancer: TNBC versus TPBC.
Yazdanpanah P; Alavianmehr A; Ghaderi A; Monabati A; Montazer M; Tahmasbi K; Farjadian S
Breast Dis; 2021; 40(1):43-50. PubMed ID: 33523034
[TBL] [Abstract][Full Text] [Related]
16. Inhibitors of PD-1/PD-L1 and ERK1/2 impede the proliferation of receptor positive and triple-negative breast cancer cell lines.
Bräutigam K; Kabore-Wolff E; Hussain AF; Polack S; Rody A; Hanker L; Köster F
J Cancer Res Clin Oncol; 2021 Oct; 147(10):2923-2933. PubMed ID: 34185141
[TBL] [Abstract][Full Text] [Related]
17. The interaction between the soluble programmed death ligand-1 (sPD-L1) and PD-1
Li X; Du H; Zhan S; Liu W; Wang Z; Lan J; PuYang L; Wan Y; Qu Q; Wang S; Yang Y; Wang Q; Xie F
Front Immunol; 2022; 13():830606. PubMed ID: 35935985
[TBL] [Abstract][Full Text] [Related]
18. Inhibition of glycolysis-driven immunosuppression with a nano-assembly enhances response to immune checkpoint blockade therapy in triple negative breast cancer.
Ren X; Cheng Z; He J; Yao X; Liu Y; Cai K; Li M; Hu Y; Luo Z
Nat Commun; 2023 Nov; 14(1):7021. PubMed ID: 37919262
[TBL] [Abstract][Full Text] [Related]
19. Comparison of the tumor immune microenvironment phenotypes in different breast cancers after neoadjuvant therapy.
Han M; Li J; Wu S; Wu C; Yu Y; Liu Y
Cancer Med; 2023 Feb; 12(3):2906-2917. PubMed ID: 36073303
[TBL] [Abstract][Full Text] [Related]
20. Efficacy and safety of PD-1/PD-L1 inhibitors in triple-negative breast cancer: a systematic review and meta-analysis.
Zhang M; Song J; Yang H; Jin F; Zheng A
Acta Oncol; 2022 Sep; 61(9):1105-1115. PubMed ID: 35939538
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
